Shilpa Medicare Ltd vs Unichem Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Shilpa Medicare Ltd is ₹ 424.4 as of 05 May 15:30 . The P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 yearsThe P/E Ratio of Unichem Laboratories Ltd changed from 63.4 on March 2021 to 35.5 on March 2025 . This represents a CAGR of -10.95% over 5 years The Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 yearsThe Market Cap of Unichem Laboratories Ltd changed from ₹ 2177 crore on March 2021 to ₹ 4877 crore on March 2025 . This represents a CAGR of 17.50% over 5 years The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The revenue of Unichem Laboratories Ltd for the Dec '25 is ₹ 808.49 crore as compare to the Sep '25 revenue of ₹ 599.93 crore. This represent the growth of 34.76% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The ebitda of Unichem Laboratories Ltd for the Dec '25 is ₹ 332.1 crore as compare to the Sep '25 ebitda of ₹ 28.89 crore. This represent the growth of 1049% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The net profit of Unichem Laboratories Ltd changed from ₹ 2.07 crore to ₹ 264.29 crore over 7 quarters. This represents a CAGR of 1497.69% The Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 yearsThe Dividend Payout of Unichem Laboratories Ltd changed from 52.07 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

About Unichem Laboratories Ltd

Unichem Laboratories Limited manufactures active pharmaceutical ingredients.
The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division.
The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh. The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia).
The Baddi plant was approved by UK MHRA and MCC (South Africa).
The company received ISO 9001:2000 for all their plants and corporate office.

FAQs for the comparison of Shilpa Medicare Ltd and Unichem Laboratories Ltd

Which company has a larger market capitalization, Shilpa Medicare Ltd or Unichem Laboratories Ltd?

Market cap of Shilpa Medicare Ltd is 8,300 Cr while Market cap of Unichem Laboratories Ltd is 2,651 Cr

What are the key factors driving the stock performance of Shilpa Medicare Ltd and Unichem Laboratories Ltd?

The stock performance of Shilpa Medicare Ltd and Unichem Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Shilpa Medicare Ltd and Unichem Laboratories Ltd?

As of May 5, 2026, the Shilpa Medicare Ltd stock price is INR ₹424.4. On the other hand, Unichem Laboratories Ltd stock price is INR ₹376.6.

How do dividend payouts of Shilpa Medicare Ltd and Unichem Laboratories Ltd compare?

To compare the dividend payouts of Shilpa Medicare Ltd and Unichem Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.